Menu Search
Equities

TELA Bio Inc

TELA:NMQ

TELA Bio Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.11
  • Today's Change0.17 / 5.78%
  • Shares traded239.10k
  • 1 Year change-32.68%
  • Beta0.9728
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year TELA Bio Inc had net income fall 5.35% from a loss of 44.30m to a larger loss of 46.66m despite a 41.13% increase in revenues from 41.42m to 58.45m.
Gross margin68.61%
Net profit margin-65.04%
Operating margin-60.01%
Return on assets-54.48%
Return on equity-196.42%
Return on investment-66.54%
More ▼

Cash flow in USDView more

In 2023, TELA Bio Inc increased its cash reserves by 11.84%, or 4.98m. Cash Flow from Financing totalled 46.27m or 79.15% of revenues. In addition the company used 40.86m for operations while cash used for investing totalled 599.00k.
Cash flow per share-1.68
Price/Cash flow per share--
Book value per share0.1163
Tangible book value per share0.0381
More ▼

Balance sheet in USDView more

TELA Bio Inc has a Debt to Total Capital ratio of 93.43%, a lower figure than the previous year's 100.52%.
Current ratio3.41
Quick ratio2.52
Total debt/total equity14.22
Total debt/total capital0.9343
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.